Mizuho Bullish on Neumora's Lead Drug Prospects, Initiates Neumora at Outperform Rating

Monday, 8 July 2024, 17:38

Mizuho has started covering Neumora Therapeutics with an outperform rating and predicts over 50% upside potential for the stock based on positive Phase 3 data for the drug navacaprant. The analysis highlights the positive outlook for Neumora and its lead drug's prospects, signaling a promising future for investors.
Seeking Alpha
Mizuho Bullish on Neumora's Lead Drug Prospects, Initiates Neumora at Outperform Rating

Mizuho Initiates Coverage of Neumora Therapeutics

Rating and Potential Upside

Mizuho has started covering Neumora Therapeutics with an outperform rating, anticipating over 50% upside potential for the stock if Phase 3 data for navacaprant is favorable.

The bullish outlook underscores the positive prospects for Neumora and its lead drug, suggesting a promising investment opportunity for interested investors.


This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Get the most reliable and up-to-date financial news with our curated selections. Subscribe to our newsletter for convenient access and enhance your analytical work effortlessly.

Subscribe